Skip to content
Homepage
Author:
X4 Pharmaceuticals, Inc.
Posted Date:
February 27, 2026
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
X4 Pharmaceuticals, Inc.
February 27, 2026
